Is it safe to use muscle relaxants in a patient with a single functioning kidney?

Use of Muscle Relaxants in Patients with a Single Functioning Kidney

Most muscle relaxants can be safely used in patients with a single functioning kidney, but specific agents should be selected based on their elimination pathways and the degree of remaining renal function.

Key Recommendations by Agent

Preferred Agents (Organ-Independent Elimination)

Atracurium and cisatracurium are the preferred muscle relaxants for patients with renal impairment, including those with a single kidney. 1, 2

• Atracurium undergoes organ-independent elimination (Hofmann degradation and ester hydrolysis), making its pharmacokinetics and pharmacodynamics similar in patients with and without kidney failure 1
• Studies in anephric patients demonstrate successful use without prolonged effects 2
• No dose adjustment is required for the initial dose 1
• Duration of action and recovery remain unchanged compared to patients with normal renal function 3, 4
• Cisatracurium is even more favorable as it is more potent, requiring lower doses and producing less laudanosine metabolite 1

Agents Requiring Caution

Rocuronium and vecuronium can be used but require careful monitoring with repeated dosing. 1, 3

• Initial dose does not require adjustment regardless of renal function 1
• Onset time remains unchanged in renal failure 1
• Duration of action becomes prolonged with repeated incremental doses in patients with end-stage renal failure 3
• Rocuronium is primarily eliminated in urine and bile, with reduced clearance in renal failure 1

Contraindicated Agents

Metaxalone is contraindicated in patients with significant renal dysfunction. 5

• Explicitly contraindicated in renal dysfunction per consensus guidelines 5
• Associated with multiple CNS adverse effects 5

Methocarbamol elimination is significantly impaired in kidney disease. 5

• Should be avoided or used with extreme caution 5
• Risk of accumulation and prolonged effects 5

Baclofen should be avoided in patients with severely reduced kidney function. 6

• Primarily excreted via kidneys 6
• Recommend avoiding use in patients with eGFR <30 mL/min/1.73 m² or on renal replacement therapy 6
• Can cause neurotoxicity and hemodynamic instability in kidney disease 6
• Dose reduction required even with moderately reduced kidney function (eGFR 30-60 mL/min/1.73 m²) 6

Agents with Acceptable Safety Profile

Cyclobenzaprine, carisoprodol, and orphenadrine do not have specific renal contraindications but carry other risks. 5

• No specific renal dosing adjustments mentioned in guidelines 5
• Concerns relate primarily to anticholinergic effects, sedation, and drug interactions rather than renal elimination 5

Clinical Algorithm for Selection

1. Assess remaining renal function - determine if the single kidney provides adequate GFR
2. For surgical/anesthetic muscle relaxation:
   • First choice: Atracurium or cisatracurium (no dose adjustment needed) 1, 2
   • Alternative: Rocuronium or vecuronium (monitor closely with repeated doses) 1, 3
3. For chronic muscle spasm management:
   • Avoid metaxalone, methocarbamol, and baclofen if GFR <30 mL/min/1.73 m² 5, 6
   • Consider cyclobenzaprine or carisoprodol with attention to non-renal adverse effects 5
4. Monitor for accumulation with any agent if using repeated or prolonged dosing 1, 3

Important Caveats

Neuromuscular monitoring is highly valuable in patients with renal impairment to detect prolonged blockade, particularly with agents like vecuronium and rocuronium after repeated dosing 4

The presence of a single functioning kidney does not automatically mean severe renal impairment - the remaining kidney may provide adequate function, but GFR should be measured to guide decisions 7

Avoid combining muscle relaxants with other nephrotoxic agents (NSAIDs, aminoglycosides) that could further compromise the remaining kidney 7